Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab PK and Safety Study in Chinese Participants with SLE
NCT05001698Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Primary endpoints: Time to Maximum Observed Plasma Concentration, Maximum Observed Plasma Concentration and 3 more. Started Jul 2021; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05001698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001698.